25K0 Stock Overview
A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Karyopharm Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.87 |
| 52 Week High | US$21.43 |
| 52 Week Low | US$7.87 |
| Beta | 0.11 |
| 1 Month Change | -11.92% |
| 3 Month Change | -29.09% |
| 1 Year Change | -58.56% |
| 3 Year Change | -91.51% |
| 5 Year Change | -96.91% |
| Change since IPO | -98.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 25K0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.9% |
| 1Y | -58.6% | -15.8% | 17.1% |
Return vs Industry: 25K0 underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: 25K0 underperformed the German Market which returned 17.1% over the past year.
Price Volatility
| 25K0 volatility | |
|---|---|
| 25K0 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 25K0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 25K0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 279 | Richard Paulson | www.karyopharm.com |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Karyopharm Therapeutics Inc. Fundamentals Summary
| 25K0 fundamental statistics | |
|---|---|
| Market cap | €47.70m |
| Earnings (TTM) | -€70.77m |
| Revenue (TTM) | €134.50m |
0.4x
P/S Ratio-0.7x
P/E RatioIs 25K0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 25K0 income statement (TTM) | |
|---|---|
| Revenue | US$145.24m |
| Cost of Revenue | US$6.01m |
| Gross Profit | US$139.23m |
| Other Expenses | US$215.65m |
| Earnings | -US$76.42m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.08 |
| Gross Margin | 95.86% |
| Net Profit Margin | -52.62% |
| Debt/Equity Ratio | -140.2% |
How did 25K0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/06 19:15 |
| End of Day Share Price | 2025/02/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Karyopharm Therapeutics Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |